PD-1/PD-L1免疫疗法是近年来癌症治疗领域的一大突破,但它并非万能。临床研究揭示了一些问题:部分患者对PD-1/PD-L1治疗无反应,而有些患者即便起初有反应,也可能发展出获得性耐药。这导致PD-1/PD-L1单药治疗的临床反应率相对较低,大约只有20%。因此,探索与PD-1/PD-L1协同作用的免疫靶点,以提高治疗效果,显得尤...
转移性黑色素瘤外泌体PD-L1 外泌体miR-21 膀胱癌细胞分泌的外泌体 外泌体LNMAT2 人真皮成纤维细胞分泌的外泌体 CAR-T细胞分泌的外泌体 心脏祖细胞(CPC)来源的外泌体 叶酸-外泌体 胶质瘤衍生的外泌体(GDEs) 常氧胶质瘤衍生的外泌体(N-GDEs) 缺氧胶质瘤衍生的外泌体(H-GDEs) 肿瘤细胞分泌的包裹仿生多...
If PD-1 is bound by the ligands (PD-L1/PD-L2), T cell function can be regulated toward reduced proliferation, decreased cytokine secretion or apoptosis. Our results showed that ERKactiveDUSP2low axis regulates PD-L1 expression in pancreatic cancer cells which can be further enhanced via ...
PDCD1LG2PD-L2/B7-DC protein, recombinant CD274PD-L1/B7-H1 protein, recombinant TNFRSF11ARANK/TNFRSF11A protein, recombinant TNFSF4OX40 Ligand/TNFSF4 protein, recombinant FCAMRFCAMR/CD351 protein, recombinant Tetraspanins 官方名通用名 CD151CD151 protein, recombinant ...
KIR2DL1KIR2DL1 PDGFRBPDGFRB KLRD1KLRD1 ART4ART4 TNFSF13TNFSF13 CD46CD46 NT5ENT5E PDCD1LG2PDCD1LG2 TNFRSF11ATNFRSF11A FCAMRFCAMR CD63 基因家族相关试剂产品 (Tetraspanins) 官方名通用名试剂列表 CD151CD151 CD53CD53 CD82CD82 ROM1ROM1 ...
CD63 functions as cell surface receptor for TIMP1 and plays a role in the activation of cellular signaling cascades. Plays a role in the activation of ITGB1 and integrin signaling, leading to the activation of AKT, FAK/PTK2 and MAP kinases. Promotes cell
艾普蒂生物工程有限公司(简称:艾普蒂)由在国内科研试剂领域有着多年从业经验的专业技术团队和企业管理团队组建而成,专门从事以抗体、蛋白、为核心的试剂产品研发与销售。 更多抗体产品信息: 兔RBBP8多克隆抗体 兔CTNNBIP1多克隆抗体 兔CTNNBL1多克隆抗体
PD-L1-Ig and mouse PD-L2-Ig to PD-1/BHK transfected cells. When administrated in vivo, both intact and Fab of J43 are reported to enhance contact hypersensitivity and exacerbate acute GVHD similar to transfer of PD-1-deficient cells. Injection of J43 also exacerbates EAE and NOD diabetes...
members of the B7 family have been identified as the PD-1 ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC). Evidence reported to date suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting ...
Abstract 6307: A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb-adc) targeting cancers co-expressing PD-L1 and CD47 In this study, we reveal another novel pegylated P-BsADC (JY207) formed by site-specific conjugation of a bispecific single chain fusion protein targeting PD-L1 an...